Glucocorticoids in pediatric inflammatory bowel disease

Area of Science:

• Pediatric Gastroenterology
• Pharmacology
• Inflammatory Bowel Disease Research

Background:

• Systemic glucocorticoids (GCs) are a primary treatment for moderate to severe pediatric inflammatory bowel disease (IBD).
• While many children initially respond to GCs, a significant portion develop steroid resistance or dependency.
• Therapy-related side effects can limit the efficacy and long-term use of GCs for controlling active inflammation.

Purpose of the Study:

• To review and summarize recent advancements in understanding glucocorticoid (GC) treatment for pediatric patients diagnosed with inflammatory bowel disease (IBD).
• To highlight the challenges associated with GC therapy, including steroid resistance, dependency, and adverse effects in children with IBD.

Main Methods:

• Literature review of recent studies and clinical trials on glucocorticoid use in pediatric IBD.
• Synthesis of current knowledge regarding the efficacy, limitations, and side effects of GC treatment in children.

Main Results:

• Glucocorticoids remain a cornerstone therapy for active pediatric IBD.
• Steroid resistance and dependency represent significant clinical hurdles, impacting treatment outcomes.
• Adverse effects associated with GC therapy necessitate careful monitoring and exploration of alternative strategies.

Conclusions:

• Effective management of pediatric IBD requires addressing GC resistance and dependency.
• Further research is needed to optimize GC therapy and mitigate side effects in children.
• Understanding current knowledge on GC treatment is crucial for improving outcomes in pediatric IBD patients.